Product Images Procainamide Hci

PROCAINAMIDE HCI INJECTION is a medication used for intravenous use after dilution. The usual dosage is provided in the insert, and it is essential not to use the injection if it has discoloration or is darker than slightly yellow. The medication contains METABISULFITES and should be stored at controlled room temperature. The product is distributed by HF Acquisition Co., LLC in Mukilteo, Washington.*

This is a description of Procainamide HCI Injection, USP used for intramuscular or intravenous administration. Each vial of the offered product contains 500mg/mL of procainamide HCI and is of 2 mL. The product comes in a box of 25 vials. The product must be used with caution as it contains metabisulfites. It is advised to not use the injection if it is darker than slightly yellow or discolored in any other way. The product must be used with aseptic technique used and stored at a controlled room temperature. The product has been manufactured by HF Acquisition Co., LLC in Mukilteo, WA. More information can be found in the manufacturer's package insert.*

This text seems to be a medical label specifying information about a drug named Procainamide Hydrochloride Injection. The medication is available in 500 mg/ml concentration and is used to treat cardiac disorders. The label includes instructions on the use and dosage of the drug as well as its composition and warnings. It also recommends using aseptic technique during the administration of the injection. There is a cautionary note on the presence of metabolites. However, the relevance of the code numbers at the beginning and end is not clear.*

The use of procainamide for a long period may cause a positive anti-nuclear antibody (ANA) test which could lead to a lupus erythematosus-like syndrome. In case of a positive ANA titer, it is recommended to evaluate the risk and benefits of continuing with the drug therapy.*

This text provides instructions for proper dilution and rates of infusion for Procainamide Hydrochloride Injection, USP. It includes a chart detailing the amount of solution to be added for an initial loading and two maintenance infusions, with recommended rates of administration. The maintenance infusion rates are calculated based on body weight, renal elimination rate, and steady-state plasma level required to control arthythmia. The use of 5% Dextrose Injection, USP is recommended for final volume. Close monitoring is advised to avoid transiently high plasma levels and possible hypotension.*

This text provides information on the Unit of Sale, Concentration, NDC (National Drug Code), and package details for a medication. The medication is available in two different concentrations - 100 mg/mL and 500 mg/mL. The NDC codes provided can be used to identify the medication. The medication is available in a case containing 25 cartons for the 100 mg/mL concentration and a bundle containing 25 cartons for the 500 mg/mL concentration.*

This is a description of a 2 mL vial of multiple-dose R procainamide solution, with a concentration of 500 mg/mL. The NDC number is 0409-1903-01 and the manufacturer is Hospira, Inc. based in Lake Forest, IL, USA. The description also includes a reference to the drug's brand name, as well as a reference to its lot number and date of manufacture.*

The text describes the results of the National Heart, Lung, and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), which examined the excessive mortality rates in patients treated with encainide or flecainide for asymptomatic non-life-threatening ventricular arrhythmias who had a myocardial infarction. Agranulocytosis, bone marrow depression, neutropenia, hypoplastic anemia and thrombocytopenia have been reported in patients receiving Procainamide hydrochloride at a rate of 0.5%, with fatalities occurring. To reduce this risk, complete blood counts should be performed regularly during the first three months of therapy, and promptly if any signs of infection, bruising, or bleeding appear. If any of these are identified, Procainamide therapy should be discontinued. The text recommends caution in patients with pre-existing marrow failure or cytopenia and highlights the proarrhythmic properties of procainamide.*